Nayak, L., Smith, T., Gaffey, S. C., Peters, K. B., Clarke, J. L., Jordan, J. T., … Reardon, D. A. (2018). Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma. In Journal of Clinical Oncology (Vol. 36, pp. 2037–2037). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.2037

Nayak, Lakshmi, Timothy Smith, Sarah C. Gaffey, Katherine B. Peters, Jennifer Leigh Clarke, Justin T. Jordan, John Frederick De Groot, et al. “Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.” In Journal of Clinical Oncology, 36:2037–2037. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.2037.

Nayak L, Smith T, Gaffey SC, Peters KB, Clarke JL, Jordan JT, et al. Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2037–2037.

Nayak, Lakshmi, et al. “Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 2037–2037. Crossref, doi:10.1200/jco.2018.36.15_suppl.2037.

Nayak L, Smith T, Gaffey SC, Peters KB, Clarke JL, Jordan JT, De Groot JF, Nghiemphu PL, Kaley TJ, Colman H, Armstrong T, Taphoorn MJ, Caruso V, Bednarek Debruyne M, Bhavsar C, Molinaro AM, Severgnini M, Wen PY, Reardon DA. Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2037–2037.